Pancreatic Cancer Research

ResearcherZhujiang HospitalActive in the last 2 years

Jian Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9257-6549; OpenAlex author ID A5061776471. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. Harnessing the power of cancer-associated fibroblasts to revolutionize pancreatic cancer treatment. Co-author DOI 10.20892/j.issn.2095-3941.2025.0288↗
  2. Local Release of TGF-β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Im… First author DOI 10.1002/advs.202105240↗
  3. HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-21-4362↗
  4. Safety and Efficacy of Irreversible Electroporation in Locally Advanced Pancreatic Cancer: An Evaluation from a Surgeon's Perspective. Co-author DOI 10.3390/cancers14225677↗
  5. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer. Co-author DOI 10.1038/s41419-021-04118-4↗
  6. ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer. First author DOI 10.3892/mmr.2018.9500↗
  7. Statin use and risk of pancreatic cancer: a meta-analysis. Co-author DOI 10.1007/s10552-012-9979-9↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 4 shared papers, 2021–2022 · strength 0.61
  2. Jun Zhao · 2 shared papers, 2022 · strength 0.34
  3. Penglin Pan · 2 shared papers, 2022 · strength 0.34
  4. L.-M. Nie · 1 shared paper, 2025 · strength 0.33
  5. Yingke Zhou · 2 shared papers, 2021–2022 · strength 0.27
  6. Dianyun Ren · 2 shared papers, 2021–2022 · strength 0.27
  7. Yan Ping Sun · 1 shared paper, 2021 · strength 0.14
  8. Yang Gao · 1 shared paper, 2021 · strength 0.14
  9. Ping Fan · 1 shared paper, 2021 · strength 0.14
  10. Xin Jin · 1 shared paper, 2021 · strength 0.14
  11. Hui Xu · 1 shared paper, 2022 · strength 0.14
  12. Teng Huang · 1 shared paper, 2022 · strength 0.14
  13. Huiming Peng · 1 shared paper, 2022 · strength 0.14
  14. Xin Long · 1 shared paper, 2022 · strength 0.14
  15. Chun Li · 1 shared paper, 2022 · strength 0.14
  16. Gengdu Qin · 1 shared paper, 2022 · strength 0.13
  17. Haixin Yu · 1 shared paper, 2022 · strength 0.13
  18. Cai‐Fang Ni · 1 shared paper, 2018 · strength 0.11
  19. Guili Xu · 1 shared paper, 2018 · strength 0.11
  20. Xiaobing Cui · 1 shared paper, 2012 · strength 0.03
  21. Bo Jiang · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.